Plasmid DNA Manufacturing Market to Exhibit at a 23.2% CAGR during the Forecast Period 2021-2027 with In-depth Analysis of Leading Players – Aldevron, Kaneka Corporation, Nature Technology Corporation

“Coherent Market Insights announced that it’s published an exclusive report namely Global Plasmid DNA Manufacturing Market by Manufacturers, Regions, Type, and Application, Forecast to 2027 in its research database with report summary, table of content, research methodologies, and data sources. The research study offers a substantial knowledge platform for entrants and investors as well as veteran companies, manufacturers functioning in the Worldwide Plasmid DNA Manufacturing Market. This is an informative study covering the market with an in-depth analysis and portraying the current state of affairs in the industry.”

Get Latest Insights in Sample Report @ https://www.coherentmarketinsights.com/insight/request-sample/2593

Global Plasmid DNA Manufacturing Market

Plasmid DNA (pDNA) plays a crucial role in modern healthcare, as it is used directly as a therapeutic agent in gene therapy or generation of vaccine antigens. Furthermore, pDNA is used as a master-template product to support production of new and emerging biopharmaceutical products and processes including RNA, in-vitro protein production, and cell therapies.
The global plasmid DNA manufacturing market was pegged at US$ 65.1 million in 2017, and is foreseen to exhibit a magnificent CAGR of 23.7% over the forecast period (2018-2026).

Increasing number of patients opting for gene therapies is expected to propel the global market expansion
Increasing number of patients opting for gene therapy is a major factor driving growth of the plasmid DNA manufacturing market. Gene therapy is a leading field in medical science, which promises new treatment development for patients suffering from various diseases. For instance, Adeno-associated AAV2 vectors carrying therapeutic gene (RPE65) intra-retinal injection leads to improved vision of individuals suffering from Leber’s Congenital Amaurosis.

Several clinical trials are being conducted on viral vectors and plasmid DNA manufacturing that are focused on the potential of gene therapy. Increasing investments in drug development and commercialization of these therapies in order to meet significant medical needs are factors driving the market growth. These genetic markers are associated with complex diseases, therefore it is important to study about the genetic information and its clinical application in designing clinical trials and gene therapy product manufacturing.

As per the data published by the Journal of Gene Medicine in March 2018, an estimated 2,600 gene therapy clinical trials has been ongoing, were already completed, or had been approved in about 36 countries. Countries where the trials were conducted include the U.S., the U.K., Australia, Canada, China, France, Germany, Japan, Switzerland, the Netherlands, and others. Moreover, diseases targeted by gene therapies include cardiovascular diseases, cancer, inflammatory and infectious diseases, Hemophilia A and B, Severe Combined Immunodeficiency (SCID), ocular diseases, neurological diseases, and others.

Collaborations by market players is expected to bolster the market growth in Europe

Europe is anticipated to witness significant growth in the global plasmid DNA manufacturing market, thanks to the increasing adoption of effective growth strategies, such as collaborations, by the key market players. For instance, in May 2018, PlasmidFactory GmbH & Co. KG collaborated with Sirion-Biotech GmbH, Vibalogics GmbH, and PROGEN for adeno-associated virus (AAV) vector manufacturing. This collaboration was done to accelerate timeline and to create easy workflow from plasmid manufacturing to GMP production, and analytics of recombinant AAV to fulfil the customers’ requirement of AAV vector.

Major Players Are Operating In The Market: Cobra Biologics and Pharmaceutical Services*, VGXI, Inc., Aldevron, Kaneka Corporation, Nature Technology Corporation, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, Waisman Biomanufacturing, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, Genscript Biotech Corporation, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., Cepham Life Sciences, Delphi Genetics, Biomiga, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd, Luina Bio Pty Ltd, Ajinomoto Bio-Pharma Services, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., and Geneone Life Science

Buy This Research Study Report (Flat US $2000 OFF) @ https://www.coherentmarketinsights.com/promo/buynow/2593

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

Contact Us

Name: Mr. Shah
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com